Form 4: Broadridge CHRO Granted 10,039 Stock Options
Executive Compensation Grant
Broadridge Financial Solutions' Corporate VP and CHRO, Richard John Stingi, was granted 10,039 stock options with an exercise price of $190.89.
Summary
- Richard John Stingi, Corporate VP and CHRO of Broadridge Financial Solutions, Inc. (BR), was granted 10,039 stock options.
- The stock options have an exercise price of $190.89 per share.
- The grant date for these options was March 5, 2026.
- The options will vest equally over four years, beginning March 5, 2027.
- The expiration date for these options is March 5, 2036.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.
Positives
- The grant of 10,039 stock options to a key executive aligns management's interests with long-term shareholder value creation.
- The vesting schedule over four years encourages executive retention and sustained performance.
Future Outlook
The stock options are structured to vest equally over four years starting March 5, 2027, aligning the executive's future incentives with the company's long-term performance.
Industry Context
StockSavvy.ai notes that equity grants, such as stock options, are a common component of executive compensation packages across the financial technology and services industry. These grants are designed to incentivize long-term performance and align executive interests with shareholder value, a practice widely adopted by peers like Fiserv (FI) and SS&C Technologies (SSNC).
Comparison to Industry Standards
- The grant of stock options with a multi-year vesting schedule is a standard practice in executive compensation, comparable to programs at companies like Fidelity National Information Services (FIS) or Global Payments (GPN), which also use performance-based equity to retain and motivate key personnel.
- The exercise price being the market price on the grant date is typical for non-qualified stock options, ensuring the executive benefits only if the stock price appreciates.
Related Party Transactions
- This filing reports an equity grant to an executive, which is a related party transaction in the context of compensation.
Stakeholder Impact
- Shareholders: The grant aligns the executive's interests with shareholder value creation, potentially leading to better long-term performance if the stock price appreciates.
- Employees: May signal stability in executive leadership and a commitment to long-term incentives.
Next Steps
- The stock options will begin vesting on March 5, 2027, over a four-year period.
- The reporting person may exercise the vested options at any time before the expiration date of March 5, 2036.
Key Dates
| Date | Description |
|---|---|
| 03/05/2026 | Date of earliest transaction (grant date of stock options). |
| 03/05/2027 | Date when stock options begin to vest equally over 4 years. |
| 03/05/2036 | Expiration date of the stock options. |
| 03/06/2026 | Date the Form 4 was signed by Power of Attorney. |
Recommendation
holdThis Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would typically warrant a change in investment recommendation. It reflects standard corporate governance and incentive practices.
Keywords
Broadridge Financial Solutions, BR, Form 4, Stock Options, Executive Compensation, Richard John Stingi, CHRO, Equity Grant, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.